BioStem Technologies Q3 revenue falls year over year
BSEM•BioStem Technologies reported third-quarter revenue of $7.64 million and a net loss of $11.4 million. It raised its 2026 revenue guidance to $28 million-$29 million from $26 million-$29 million and expects cost reductions to lower annualized cash operating expenses by $10 million-$12 million from 2027.
1. Quarterly results
BioStem Technologies said third-quarter revenue fell year over year to $7.64 million. The company reported a net loss of $11.4 million, or $0.64 per share. Hospital revenue increased sequentially as the company added accounts and expanded business with existing customers.
2. Raised guidance
BioStem raised its 2026 revenue guidance to $28 million-$29 million from $26 million-$29 million. It expects in-house production of Neox and Clarix to begin in the first half of 2027.
3. Planned cost reductions
BioStem is finalizing a cost reduction plan expected to cut annualized cash operating expenses by $10 million-$12 million, with the full benefit expected in the first quarter of 2027. The company said gross margin fell sequentially due to higher pricing under its BioTissue supply agreement after discounted pricing expired.
